OMNIRAY: a Phase 1 Clinical Trial for LY4257496 for mCRPC

/0 Comments/in , , /by

The OMNIRAY trial will be investigating LY4257496, a novel radioligand therapy and it is set to begin in August 2025. This phase 1a/1b, multicenter, open-label study aims to establish the safety, tolerability and dosimetry of LY4257496 in adult patients bearing advanced solid tumors that express the gastrin-releasing peptide receptor (GRPR). The trial proposes a two-part […]

Read more

Nuanced Benefits of Fasting-Mimicking Diets: High Protein vs. Low Protein

/0 Comments/in /by

A recent study published in Clinical Nutrition sheds new light on the physiological impacts of Fasting-Mimicking Diets (FMDs), revealing that while both low-protein and high-protein versions offer significant health advantages, their specific benefits can differ notably. This randomized controlled trial explored the effects of a 7-day plant-based FMD with either a low protein/high fat (LP-FMD) […]

Read more

Newsletter 33/2025

/0 Comments/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! We have 3 clinical and 3 preclinical research today, but since the second half of August is always a bit “slow,” so I took the opportunity to create an article of my own that tries to summarize almost a […]

Read more

Update: HLD-0915 Advances with FDA Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer

/0 Comments/in , , , /by
Read more

APVO442: A Promising Preclinical Candidate in the Fight Against Prostate Cancer

/0 Comments/in , /by

A Seattle-based biotech, is stepping up with APVO442, a promising preclinical bispecific antibody aimed at transforming prostate cancer treatment by unleashing the body’s immune system against tumors with greater precision and fewer side effects. Built on proprietary ADAPTIR-FLEX platform, APVO442 is designed to target prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer […]

Read more